Access to care for Chagas disease in the United States: A health systems analysis

American Journal of Tropical Medicine and Hygiene

Volumn 93, Issue 1, 2015, Pages 108-113

  Manne Goehler, Jennifer ^a   Reich, Michael R ^b   Wirtz, Veronika J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX; ANTITRYPANOSOMAL AGENT; NEW DRUG; NITROIMIDAZOLE DERIVATIVE;

ARTICLE; AWARENESS; BLOOD DONOR; CHAGAS DISEASE; CLINICAL EVALUATION; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; PATIENT CARE; PERSUASIVE COMMUNICATION; SCALE UP; SEMI STRUCTURED INTERVIEW; UNITED STATES; CLINICAL COMPETENCE; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PATIENT REFERRAL; PUBLIC HEALTH SERVICE; SYSTEM ANALYSIS;

BLOOD DONORS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHAGAS DISEASE; CLINICAL COMPETENCE; DELIVERY OF HEALTH CARE; DRUGS, INVESTIGATIONAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; NIFURTIMOX; NITROIMIDAZOLES; REFERRAL AND CONSULTATION; SYSTEMS ANALYSIS; TRYPANOCIDAL AGENTS; UNITED STATES;

EID: 84937002067     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.14-0826     Document Type: Article

References (22)

1. Mathers CD, Ezzati M, Lopez AD, 2007. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 1: e114.
2. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman GH, Reyes PA, Salvatella R, Moore AC, 2007. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298: 2171-2181.
3. Manne JM, Snively CS, Ramsey JM, Salgado MO, Ba¨rnighausen T, Reich MR, 2013. Barriers to treatment access for Chagas disease in Mexico. PLoS Negl Trop Dis 7: e2488.
4. Albajar-Vinas P, Dias JC, 2014. Advancing the treatment for Chagas' disease. N Engl J Med 370: 1942-1943.
5. Ribeiro I, Sevcsik A-M, Alves F, Diap G, Don R, Harhay MO, Chang S, Pecoul B, 2009. New, improved treatments for Chagas disease: from the R and D pipeline to the patients. PLoS Negl Trop Dis 3: e484.
6. Gascon J, Bern C, Pinazo MJ, 2010. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop 115: 22-27.
7. Bern C, Montgomery SP, 2009. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49: e52-e54.
8. Albajar-Vinas P, Jannin J, 2011. The hidden Chagas disease burden in Europe. Euro Surveill 16: 2-4.
9. Verani JR, Montgomery SP, Schulkin J, Anderson B, Jones JL, 2010. Survey of obstetrician-gynecologists in the United States about Chagas disease. Am J Trop Med Hyg 83: 891-895.
10. Roberts MJ, Hsiao W, Berman P, Reich MR, 2004. Getting Health Reform Right: A Guide to Improving Performance and Equity. Oxford, United Kingdom: Oxford University Press.
11. Frost LJ, Reich MR, 2008. Access: How Do Good Health Technologies Get to Poor People in Poor Countries. Cambridge, MA: Harvard Center for Population and Development Studies, distributed by Harvard University Press.
12. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, Roddy P, Parreño F, Viñas PA, Palma PP, 2009. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis 3: e488.
13. Bern C, 2011. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 364: 2527-2534.
14. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A, 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734.
15. American Association of Blood Banks, 2013. AABB Confirmed Chagas Cases, 2007-Present. Bethesda, MD: American Association of Blood Banks.
16. United States Centers for Disease Control and Prevention Drug Service, 2014. Drug Releases for Chagas disease in the United States, 1992-Present. Atlanta, GA: United States Centers for Disease Control and Prevention.
17. U.S. Food and Drug Administration, 2014. CFR - Code of Federal Regulations Title 21. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312. Accessed June 4, 2014.
18. Stimpert KK, Montgomery SP, 2010. Physician awareness of Chagas disease, USA. Emerg Infect Dis 16: 871-872.
19. Global Funding of Innovation for Neglected Diseases, 2013. Neglected Disease Research and Development: The Public Divide. Sydney, Australia: Policy Cures.
20. James AB, Hillyer CD, Shaz BH, 2012. Demographic differences in estimated blood donor eligibility prevalence in the United States. Transfusion 52: 1050-1061.
21. Garcia MN, Aguilar D, Gorchakov R, Rossmann SN, Montgomery SP, Rivera H, Woc-Colburn L, Hotez PJ, Murray KO, 2015. Evidence of autochthonous Chagas disease in southeastern Texas. Am J Trop Med Hyg 92: 325-330.
22. Montgomery SP, Starr MC, Cantey PT, Edwards MS, Meymandi SK, 2014. Neglected parasitic infections in the United States: Chagas disease. Am J Trop Med Hyg 90: 814-818.